SCT and migraine disorder: Therapeutic monoclonal antibodies against several classes of GPCRs have been described including secretin-class GPCRs,41 one example being AMG 334 (Erenumab) targeting the Calcitonin Gene-Related Peptide Receptor42 which has now reached the market and is used in migraine prevention.